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Abstract
Purpose of Review The treatment of non-union fractures represents a significant challenge for orthopaedic surgeons. In recent
years, biologic agents have been investigated and utilised to support and improve bone healing. Among these agents, platelet-rich
plasma (PRP) is an emerging strategy that is gaining popularity. The aim of this review is to evaluate the current literature
regarding the application and clinical effectiveness of PRP injections, specifically for the treatment of non-union fractures.
Recent Findings The majority of published studies reported that PRP accelerated fracture healing; however, this evidence was
predominantly level IV. The lack of randomised, clinical trials (level I–II evidence) is currently hampering the successful clinical
translation of PRP as a therapy for non-union fractures. This is despite the positive reports regarding its potential to heal non-
union fractures, when used in isolation or in combination with other forms of treatment.
Summary Future recommendations to facilitate clinical translation and acceptance of PRP as a therapy include the need to
investigate the effects of administering higher volumes of PRP (i.e. 5–20 mL) along with the requirement for more prolonged
(> 11 months) randomised clinical trials.
Keywords Bone healing . Fracture . Non-union . Platelet-rich plasma (PRP)
Introduction
The US Food and Drug Administration (FDA) defines a long
bone non-union as a fracture that has failed to heal within the
first 9 months following injury and has shown no signs of
healing for at least 3 consecutive months [1]. However, there
is currently no standardised system to define a non-union, so
fractures can also be classified as a non-union outside of these
parameters (Table 1). The diagnosis of non-union is depen-
dent upon a number of factors including the location of injury,
since healing times vary depending upon the type and location
of the bone; and weight-bearing bones, such as the femur and
tibia, often require the longest healing times to achieve union
[2]. A fracture can also be classified by a clinician as a ‘non-
union’ when he/she believes the fracture has little or no po-
tential to heal [3]. Specific examples of this arise when there is
a persistent gap at the fracture site several months following
the initial injury, and/or in instances whereby the patient suf-
fers from persistent pain at the fracture site long after the initial
pain of the break has occurred [4].
Impaired healing occurs in 10–15% of fracture patients,
which ultimately can lead to a non-union [5]. Characteristics
of an impaired healing process include persistent pain, poor
bridging of the fracture site by callus formation and a persis-
tent radiolucent line at the fracture which can be visualised via
X-ray [6]. Risk factors associated with non-union include in-
creasing age and alcohol consumption, smoking and deficien-
cies in vitamin D, calcium or protein [4].
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Non-union fractures provide a socioeconomic burden that
puts pressure on already strained healthcare systems [6]. In the
UK, the average cost of long bone non-union treatment is
£29,204 per patient; in Canada, 67–97% of the total costs of
tibia fractures were specifically related to non-unions in 2014
[7]. Within European healthcare systems, this range narrowed
to 82.8–93.3% in the same year [7]. Non-unions are a signif-
icant source of morbidity and have a serious impact on patient
quality of life (QoL). This is because delayed healing requires
additional hospitalisation and the requirement for extensive,
often uncomfortable surgical treatments which take, on aver-
age, a further 4–8 months to recover from (assuming no fur-
ther issues arise during treatment and rehabilitation) [7]. The
current ‘gold standard’ for treatment of non-union fractures is
the use of autologous cancellous bone grafts [8]. Bone from
another part of the body is transplanted to the non-union site
where it can act as a scaffold on which new bone can grow.
Bone grafts provide the non-union site with a fresh source of
bone cells to help ‘jump start’ the healing process [4].
However, researchers are currently exploring alternative ther-
apies and treatment options, largely due to the limited supply
and donor site morbidity associatedwith autologous grafts [8].
One potential alternative, which is gaining popularity in the
literature, is the use of platelet-rich plasma (PRP).
The aim of this review is to use the current literature to
evaluate the effectiveness of PRP in accelerating the healing
of non-union fractures. This can be used to inform as to
whether PRP may eventually have the potential to become a
primary treatment perceptive option.
Methods
As a part of the systematic literature search, the following
inclusion criteria were utilised: clinical reports of any level
of evidence, published in the last 20 years (2000–2020) using
PRP for the treatment of fractures, with a specific focus on
non-unions. Keyword strings of (((‘platelet rich plasma’ OR
‘PRP’))) AND ((‘bone fracture’ OR ‘non-union fracture’ OR
‘delayed healing’)) AND (‘human’ OR ‘clinical’) were used
to identify relevant English language articles using the elec-
tronic database, PubMed. Scopus, Google Scholar and
Springer were also utilised to search for additional resources.
Results
Using the search terms described returned 38 articles that were
eligible for inclusion. The removal of duplicate records result-
ed in 29 records being screened for relevance (Fig. 1). The
titles and abstracts were screened, and 7 articles were removed
since they were unrelated and/or review articles, book chap-
ters or conference proceedings. Four articles were removed
since they referred to soft tissues. Eighteen studies were in-
cluded in a qualitative synthesis. Due to the diversity of pro-
tocols implemented and the significant variation in outcome
measures that were reported, it is extremely difficult to directly
quantitatively compare the studies. Thus, a narrative critique
was deemed to be most appropriate to review and present the
relevant literature. The search revealed that the vast majority
of literature has reported benefits of PRP in accelerating bone
regeneration. The optimum dose of PRP for treating non-
unions is currently undetermined, and the lack of
standardisation regarding the preparation and delivery of
PRP is retarding clinical translation. Therefore, this review
also aims to provide recommendations for successful clinical
translation, uptake and acceptance.
PRP and Its Role in Regeneration
The use of PRP in tissue regeneration is a rapidly evolving
area for both clinicians and researchers and is being employed
in various fields, including osteoarthritis [9], rotator cuff repair
[10, 11] and bone regeneration [12]. This is because autolo-
gous platelet concentrations offer an easy, cost-effectivemeth-
od to obtain the high concentrations of specific growth factors




Inadequate immobilisation, yet adequate blood supply. In radiographs, callus formation is decreased with an
elephant-foot or horseshoe configuration observed.
Atrophic (avascular, non-viable,
avital)
Poorly vascularised non-union, resulting in poor potential for forming bone cells and, therefore, delayed healing.
There is little callus formation around the fibrous tissue–filled fracture gap.
Oligotrophic The body can initiate a healing response but is unable to complete the fracture formed between the two ends of the
bone.
Septic A bacterial infection impedes the healing process. Typical bacterial strains that inflict non-union sites include
coagulase negative Staphylococcus spp. and Propionibacterium spp.
Pseudoarthrosis Persistent motion at fracture site causes formation of false joint (joint that develops at the site of a fracture), often
producing synovial fluid.
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including platelet-derived growth factor (PDGF), vascular en-
dothelial growth factor (VEGF), transforming growth factor
(TGF beta 1 and 2) and insulin-like growth factor (IGF-1)
which are required for tissue healing and regeneration [9]. A
healthy individual has a baseline platelet count between 1.5
and 4.5 × 105/μL [12]; to be deemed as therapeutically bene-
ficial, a platelet concentration of 4–5 times that of baseline
should be present. The preparation of PRP varies slightly in
published literature. However, in general, blood is drawn into
a tubewhich is often treated with an anticoagulant [13]. This is
followed by centrifugation and activation of the platelets via a
chemical agent [13]. Frequently used activators include calci-
um chloride [13–19] and bovine [17, 20] or autologous throm-
bin [15, 21, 22]. Thrombin forms a gel-like substance, from
which the PRP can be extracted and directly applied to the
patient intravenously [14, 17, 23].
Within platelets are granules, which contain numerous
growth factors and cytokines that are important in the early
stages of bone repair [12]. On activation, following clotting,
these platelets release these growth factors, which play a crit-
ical role in the production of proteins required for regenerative
processes, such as cellular proliferation, matrix formation, os-
teoid production and collagen synthesis [12].
Current Use of PRP in Non-union Fractures
Clinical trials have investigated the effect of PRP on non-
union healing alone [14, 21, 24, 25] and in combination with
other forms of treatment such as the use of mesenchymal stem
cells (MSCs) [26, 27], internal fixation and/or nailing [16, 19,
23, 28–30]. When using PRP in isolation to treat a non-union,
the therapeutic benefit is divided; in some instances, PRP has
been deemed successful in achieving bony union at the frac-
ture site [24, 25, 31] within 11 months of initial injury or
surgery [17]. In addition, PRP has been shown to enhance
the healing of non-unions when used in conjunction with other
forms of treatment such as the ‘gold standard’ autologous
bone graft [32, 33], as well as MSCs [27, 34] and internal
fixation [16, 28, 29]. Despite the majority of literature
reporting the success of PRP in accelerating healing, it has
been found to have less of an effect when compared to other
forms of treatment, most importantly the use of bone morpho-
genetic proteins (BMPs), such as rhBMP-7 [35]. This is most
likely due to the low concentration of growth factors which
can be extracted with PRP in comparison to BMPs [36].
Among the literature concerning the use of PRP specifical-
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Fig. 1 Prisma flowchart of study
selection criteria
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lack of prospective randomised clinical trials (RCTs) and,
therefore, a minimal amount of literature with level I–III evi-
dence. Instead, studies are predominantly in the form of case
series or preliminary studies (level IV evidence) [14–19, 22,
24–27, 29, 31]. The advantage of case series is that they are
relatively easy to conduct whilst requiring less time and finan-
cial resources in comparison to RCTs, cohort or case-control
studies. However, the limitations include a lack of control
subjects, which leaves the interpretation of results open to
bias. Not only are the majority of published PRP studies case
series, but the studies are also predominantly pre-clinical
(Fig. 2). Fortunately, the most recent literature [14, 15, 22,
31], summarised by Roffi et al. [37], demonstrated that studies
are moving towards a more clinical direction, which is vital for
successful translation of any therapy.
PRP Preparation and Administration
Despite PRP being widely used for several musculoskeletal
pathologies [9–11], there is currently a lack of standardisation
with regard to the how PRP is prepared and delivered for
treatment of non-union fractures. In general, the PRP prepa-
ration process involves the processes of collection, centrifuga-
tion to separate out the platelets, extraction of platelet-rich
plasma from the red blood cells and platelet poor plasma
and activation using an anticoagulant agent (although this is
not always the case) followed by administration to the injury
site (Fig. 3).
During preparation, the process of centrifugation is
utilised for concentrating platelets in all literature.
However, the rates of centrifugation differ between stud-
ies, ranging from 3200 up to 5200 rpm [15, 19, 21, 30],
which leads to different relative forces depending on rotor
length, while other studies do not state the rate [7, 35].
Furthermore, centrifugation can potentially lead to the
fragmentation of the platelets and the early release of
growth factors which will ult imately reduce the
bioactivity of the PRP [15]. Thus, activation of the PRP
could be influenced by the relative centrifugal forces be-
tween studies causing unwanted variation. Therefore, it is
recommended that future studies consider ultrafiltration,
which potentially offers a more standardised process for
PRP extraction [17].
Activation of PRP via the use of chemical anticoagulant
agents is also a key component of the preparation process.
Throughout the literature, this activator varies, with throm-
bin, calcium chloride and calcium gluconate being the
most common. Thrombin is often combined with calcium
chloride (CaCl2) [19, 20] or calcium gluconate [15, 21] in
an attempt to further increase activation of the platelets. In
some literature, details regarding activator use are absent
[31], with some studies using none at all [24]. Different
reagents have differing half-lives [38], which also has an
impact on the duration of the anticoagulant to clear the
system. This in turn will have an impact on PRP activation
and, therefore, have an impact on the rate of bone regen-
eration and PRP efficacy. Furthermore, anticoagulant use,
particularly those with prolonged half-lives, may limit the
suitability of PRP as a therapy for some patient groups
including those with anaemia and renal diseases [39].
When analysing PRP delivery methods, it was noted that
the volume of PRP delivered varies significantly between
studies, with the dose of a single injection varying from
2.5 ml [14] up to 20 ml [24]. The total dose is usually given
to a patient as a single dose [21, 24], but may also be
divided into multiple injections over consecutive weeks
[14, 25] (Table 2). This will likely cause differing levels
of efficacy between methods of application as injecting a
single dose in comparison to the same dose being divided
over several weeks will impact upon the rate of bone re-
generation. Dividing a set dose over a period of several
weeks will likely delay the intended effect of the injection,
slowing the rate of non-union healing. Conversely, the ap-
plication of multiple equivalent doses of PRP over a
Fig. 2 The current proportions of
pre-clinical and clinical studies
investigating the use of PRP for
the treatment of bone defects from
2005 to 2016, reproduced from
Roffi et al. (2017) [37] with
permission from copyright owner
(the authors)
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prolonged period may increase healing rates, although it is
impossible to say for certain since rate of healing is patient
specific and RCTs would need to be performed to clarify
this.
The Impact of PRP Activation on Bone Regeneration
The majority of published studies currently fail to report key
aspects such as platelet concentrations, leukocyte components
and activation modalities [37]. This is despite Chen et al. dem-
onstrated how a medium concentration of PRP (2.65 ± 0.2 ×
109/mL) induces oestrogenic differentiation of bone marrow
stem cells (BMSCs/BM-MSCs), improving fracture healing,
whereas a high concentrations of PRP (8.21 ± 0.4 × 109/mL)
can inhibit osteogenic differentiation and delay callus remod-
elling [40]. Labibzadeh et al. reported that leukocyte-rich PRP
induced higher proliferation of BMSCs [27], while other lit-
eratures have found activation modality to influence the mol-
ecules released by the PRP [41]. This highlights that differing
concentrations and ultimately levels of activation will affect
the efficacy of the therapy.
The Use of PRP in Isolation to Treat Non-union
Fractures
Once PRP has been prepared, treated with an anticoagulant and
activated, it is often then applied alone as a form of treatment.
Only one study reported PRP to be unsuccessful in achieving
union when used in isolation [14]. The study comprised 20 pa-
tients, 12 of which were diagnosed with a non-union fracture.
These subjects were treated weekly for 6months [14]. No patient
achieved union up to 10 months following treatment. Therefore,
the authors concluded that PRP was ineffective in treating non-
unions [14]. However, the administration of the PRP was a lim-
itation of the study. A total of 2.5 mL of PRP activated by
calcium chloride was injected each week for 3 weeks. A
2.5 mL dose of PRP is relatively small in comparison to other
studies; however, it is impossible to determine how the harvest
blood and/or delivery volume used in any study compares to the
number of platelets and/or leukocytes isolated, since this value is
very rarely stated in published studies (Table 2). Furthermore, the
size of non-union is widely varying when comparing patients
within study groups and separate studies to each other.
Moreover, the size/volume of the non-union is not always pre-
scribed in published studies. PRP has been a reported success
with a dose of at least 5 mL per injection [28, 30], often applied
on at least three separate occasions [25, 31] In addition to this, the
PRP was activated using calcium chloride. In the majority of
published literature where PRP has successfully induced union,
bovine/autologous thrombin was utilised in the activation pro-
cess [15, 17–19, 21, 22, 28], thus implying that activation using
calcium chloride alone and the lower dose of PRP could poten-
tially be key factors in the unsuccessful union of these patients’
fractures.
Despite its common use, bovine thrombin as an activator has
been questioned in clinical application, since disease transmis-
sion, possible carcinogenesis, availability and cost are all issues
related to bovine thrombin [20]. Furthermore, Malhotra claimed
that sufficient thrombin is produced via local trauma when the
fracture site is infiltrated with a needle [24]. To test this hypoth-
esis, a high volume of 20 mL of PRP was injected on one occa-
sion without thrombin and with a high concentration of platelets
(approximately 5 times normal values) [24]. Eighty-seven per-
cent of patients achieved union at the end of the 4-month follow-
up period. All of which had an average time of 9.1 months be-
tween the injury and the PRP injection [24].
In 2008, Bielecki et al. concluded that PRP is a sufficient
method to achieve union as long as the treatment occurs ≤
11 months following initial surgery [17]. In Malhotra et al.’s
study, the 13% of patients who had previously not achieved
union were treated with PRP over 12 months following initial
diagnosis. However, following the conclusions of Bielecki et al.,
due to the delay in PRP treatment from diagnosis, the fracture
gap most likely became too large for the PRP to have a regener-
ative effect. Limitations that were acknowledged in the study
were that it was not a RCT and only involved non-unions which
had more than 90% contact between the fracture fragments.
Therefore, findings from this study may not be applicable to
more severe non-unions. A more recent study by Tawfik et al.
had similar inclusion criteria (more than 90% contact between













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the fracture fragments) and dose of PRP (20 mL) and found very
similar rates (85%) of union among patients [21] in comparison
to Malhotra et al. (87%).
PRP as a Hybrid Treatment
PRP can also be utilised in combination with other forms of
non-union fracture treatment, including autografts, compres-
sion plates and/or fixation devices [13, 15, 19, 27, 28, 30, 31].
Some studies have investigated the effect of combining PRP
with an iliac crest autograft and concluded that the addition of
PRP has the potential to enhance healing [13, 22, 30]. However,
in these studies, the authors could not attribute the healing of the
fracture to the addition of PRP in isolation, due to the lack of
randomised control groups. Therefore, no information could be
provided regarding the efficacy of one particular method. This
is apparent in the case of Tarallo et al. where patients were
treated using a bone graft, dynamic compression plate and
PRP [22]. Despite this, union was achieved in 90% of cases
with an average time to union of 4 months. Ghaffarpasand et al.
conducted the only randomised double blinded placebo-
controlled clinical trial investigating the effect of PRP on the
rate of healing of non-union fractures treated with an autolo-
gous bone graft and internal fixation. Patients received either
5 mL of PRP or 5 mL of saline (placebo) during surgery. The
healing rate was significantly higher in the PRP group in com-
parison to that in the control (81.1% vs. 55.3%, p = 0.025) [30].
Reports on the effectiveness of PRP and autograft fixation as a
non-union fracture treatment are divided. Case series findings
have largely been positive in terms of improved rates of non-
union healing [13, 17, 20, 26]. Though, the rate of healing cannot
be attributed to the use of PRP due to a lack of effective controls.
However, in a unique case series byMariconda et al., the healing
rate of union of patients treated with PRP and external fixation
(90%) was compared to the healing rate of union of a historical
control group (85%), with no significant clinical usefulness of
PRP being reported [15]. However, caution should be taken
when interpreting this result, since the sample size was relatively
small (n = 20), limiting the statistical power of the data. A recent
randomised, controlled clinical trial regarding the combined use
of PRP and internal fixation [28] reported that the addition of
PRP to internal fixation significantly increased the rate of healing
(94% vs. 78%, p< 0.05) whilst reducing healing time (91.6 ± 6.9
vs. 115.2 ± 8.4 days, p < 0.05) in comparison to a control group
[28]. The study had not only the primary measure of healing rate
but also secondary outcome measures assessed using a visual
analogue scale (VAS). The VASwas used to measure subjective
characteristics that cannot be directly measured such as pain
intensity, treatment costs and adverse reactions; all of which are
important aspects in a method of treatment [28], particularly
when considering clinical acceptance and translation. Since
PRP elevated the healing rate, this shortened the treatment time


































































































































































































































































































































































































































































































































































































































































































































































































































































Two case studies have been conducted investigating if the
combination of PRP and MSCs can facilitate healing of non-
union fractures, both reporting success with the method [27,
34]. Labibzadeh et al. stated that, when combined with MSCs,
PRP is successful in patients who had previously failed to
achieve union using the ‘gold standard’ iliac bone graft. This
highlights how effective PRP could be in improving bone regen-
eration in difficult cases of non-union [27]. However, Centeno
et al. did reveal a limitation of the method, including the fact that
the MSCs isolated from bone marrow aspirate obtained from the
iliac crest required a second invasive surgical intervention. This
increased the potential risk of infection and causes further pain to
the patient [34]. Moving forward, double blinded, controlled
trials are still required to assess the clinical efficacy of this
treatment.
The Use of PRP vs. Alternative Treatments
In a well-documented, prospective RCT, it was suggested that
rhBMP-7 was a superior bone-stimulating agent compared to
PRP. Rather than being injected into the site of the non-union,
both PRP and rhBMP-7 were applied locally during revision
surgery allowing both methods to be directly compared.
Subjects (n= 120) in the PRP group had an average non-union
duration of 19.2 ± 2.86months [35]. As discussed above, Bielecki
et al. proposed that, for PRP to be a success, the treatment should
be made within 11 months of injury or initial surgery [17]. This
would suggest that, whilst the rate of union in the PRP group was
significantly lower (68.3% PRP vs. 86.7% rhBMP-7), the find-
ings of this study should be interpreted with caution. The authors
concluded that administering PRP alone without a bone graft
could be deemed non-ideal in terms of exploiting PRP’s innate
bone regeneration enhancement capabilities [35]. Since the study,
PRP has demonstrated success alone in accelerating rate of union
[7, 21, 29], with the majority of the literature investigating the
potential of PRP to enhance current treatment strategies [20, 28,
30]. Thus, it is unlikely that PRP as a therapy will be used alone
on a large scale. However, PRP could potentially be applied as a
minimally invasive method as a way of saving resources in med-
ical care, with no significant difference being found between PRP
and intramedullary nailing in achieving union [19]. Larger,
randomised controlled studies under optimal treatment conditions
are needed to give more powerful and accurate results.
Conclusion
The consensus from the literature is that PRP is effective in accel-
erating the healing of non-union fractures. The success it has
demonstrated when used in isolation ranges in doses from 2.5 to
20 mL, implying that it could potentially become a primary form
of treatment.However, the non-unionwould have to be inherently
stable and PRP would ideally be administered within 11 months
of injury or initial surgery, although further investigation is needed
to confirm this barrier. Moving forward, it is recommended that
RCTs should focus on the effect of injections of at least 5 mL of
PRP, since lower doses have not been reported as successful in
inducing bone regeneration [14]. The study by Malhotra et al., a
major contribution to the research, suggested that the common
activator bovine thrombin may not be a necessity [24] and this
should be investigated further in future studies to determine
whether sufficient thrombin is produced via local trauma when
the fracture site is infiltrated with a needle in order to activate the
platelets. Other major contributions include the work by
Ghaffarpasand et al. and Zhao et al., whereby they have demon-
strated the success of PRP and internal fixation as a combination
treatment [28, 30].However,moreRCTSareneeded to determine
if PRP is a more effective bone-stimulating agent for augmenting
union in comparison to the likes ofMSCs and BMPs. Finally, the
most effective method of PRP preparation (rate of centrifugation/
ultrafiltration, activator, dose, etc.) and administration (single or
multiple injections) needs to be systematically investigated and
standardised in order for the therapy to develop further.
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